In Vitro |
Plumbagin (0, 5, 10, and 15 μM) induces apoptosis of prostate cancer cell lines, such as DU145, CWR22rv1 and LNCaP, in a dose-dependent manner[1]. Plumbagin (5, 20 μM) obviously inhibits the invasion of PC3, DU145, and CWR22rv1 cells[1]. Apoptosis Analysis[1] Cell Line: DU145, CWR22rv1, LNCaP and RWPE-1 cells Concentration: 0, 5, 10, and 15 μM Incubation Time: 24 hours Result: Dose-dependently induced apoptosis of DU145, CWR22rv1 and LNCaP, but showed no effect on RWPE-1 cells at up to 20 μM.
|
In Vivo |
Plumbagin (2 mg/kg, i.p., five days a week for 11 weeks) inhibits the growth of tumor in male athymic nude mice[1]. Plumbagin (2 mg/kg, i.p., five days a week for 11 weeks) inhibits expression of PKCε, suppresses JAK-2 and Stat3 phosphorylation, and activates Stat3, PCNA, VEGF and MMP-9 in mice[1]. Animal Model: Male athymic nude mice bearing DU145 cells[1] Dosage: 2 mg/kg Administration: I.P. after 3 days post cell implantation, five days a week. Result: Delayed tumor growth by 3 weeks, and reduced tumor weight and volume in mice.
|